Tempest: Roche to Support Combo Therapy Hepatocellular Carcinoma Trial

 Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced an agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq®) and bevacizumab, the current standard of care for unresectable or metastatic hepatocellular carcinoma (HCC), into a pivotal Phase 3 trial for the first-line treatment of unresectable or metastatic hepatocellular carcinoma, a form of liver cancer with high unmet need.

https://www.globenewswire.com/news-release/2024/10/10/2961185/0/en/Tempest-Announces-Agreement-with-Roche-to-Support-Advancement-of-Amezalpat-Combination-Therapy-into-First-Line-Hepatocellular-Carcinoma-Pivotal-Trial.html